PMC:7195088 / 10037-10307 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"170","span":{"begin":19,"end":27},"obj":"Species"},{"id":"171","span":{"begin":206,"end":214},"obj":"Species"},{"id":"204","span":{"begin":4,"end":15},"obj":"Chemical"},{"id":"242","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"243","span":{"begin":197,"end":205},"obj":"Disease"}],"attributes":[{"id":"A170","pred":"tao:has_database_id","subj":"170","obj":"Tax:9606"},{"id":"A171","pred":"tao:has_database_id","subj":"171","obj":"Tax:9606"},{"id":"A204","pred":"tao:has_database_id","subj":"204","obj":"MESH:C502936"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:C000657245"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not av"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T51","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"T52","span":{"begin":197,"end":205},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not av"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T32","span":{"begin":103,"end":108},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":" of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not av"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T44","span":{"begin":4,"end":15},"obj":"Chemical"},{"id":"T45","span":{"begin":103,"end":108},"obj":"Chemical"}],"attributes":[{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A45","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":" of tocilizumab to patients with COVID-19 should preferentially occur within the framework of RCT. Off-label use according to local protocols and consent procedures may be considered only in those COVID-19 patients excluded from RCT (or hospitalized where RCT are not av"}